关键词: 肺动脉高压, 右心衰, 吸入左西孟旦, 安全性 , 有效性

Abstract: Pulmonary hypertension (PH) is a serious disease characterized by abnormally high pulmonary arterial pressure (PAP), which leads to increased heart burden and may eventually lead to right heart failure. Seriously affect the quality of life and prognosis of patients. Levosimendan, as a calcium sensitizer, has the dual role of enhancing cardiac contractility and promoting vascular dilation. At present, levosimendan shows a good prospect in the treatment of PH combined with right heart failure, because it can reduce PAP, increase the contractile force of right ventricle (RV), and reduce the anteriorventricular load without increasing myocardial oxygen consumption. Since it does not increase the intracellular Ca2 + concentration, it does not exhibit the arrhythmogenic or even induced reduction in coronary perfusion that other positive inotropic drugs have. Currently, levosimendan is mainly treated by peripheral or central intravenous infusion, which can lead to side effects such as systemic hypotension. Inhalation of levosimendan directly acts on pulmonary vessels and may reduce the risk of systemic adverse reactions. However, the use of inhaled levosimendan in PH with right heart failure is still in the exploratory stage, and its efficacy and safety remain to be studied. To this end, the purpose of this paper is to understand the role of inhaled levosimendan in PH combined with right heart failure.

Key words: pulmonary hypertension, right heart failure, inhaled levosimendan, safety , efficacy